



# CYduct Diagnostics Granted Patent for Precision Medicine-Based Breast Cancer Risk Assessment Test

---

*Breakthrough Innovation Aims to Enable the Earliest Possible Detection of Breast Cancer*

WESTPORT, CT, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- CYduct Diagnostics, Inc. (OTCPK: CYDX), a leader in women's health and precision medicine, today announced that it has been granted a U.S. patent for its proprietary breast cancer risk assessment test. This groundbreaking diagnostic technology is designed to identify breast cancer risk at its earliest stages, representing a significant advancement in the early detection and prevention of one of the world's deadliest diseases.

The newly patented test utilizes a precision medicine-based approach, leveraging targeted biomarkers and advanced automated ELISA technology to detect subtle biological changes in noninvasively collected patient samples. By identifying risk indicators before traditional imaging methods can detect the disease, CYduct's innovation has the potential to transform the standard of care for millions of women globally.

"This patent marks a major milestone in our mission to bring more effective, accessible, and proactive breast cancer health tools to the forefront of women's healthcare," said Dominick Gatto, Chief Executive Officer at CYduct Diagnostics. "By moving risk assessment and diagnosis further upstream, we empower women and their physicians with critical knowledge—potentially years before traditional methods would detect a problem."

Breast cancer continues to affect more than 2.5 million women each year worldwide, with survival rates closely tied to how early the disease is diagnosed. CYduct's patented test aims to close the critical gap in early detection, offering a noninvasive, data-driven tool that prioritizes accuracy, reproducibility, and personalized risk evaluation.

This innovation builds on CYduct's broader research initiatives, including an ongoing study supported by the Dr. Susan Love Fund for Breast Cancer Research at the Tower Cancer Research Foundation. The study explores targeted biomarker combinations to further refine early detection strategies and reduce the need for aggressive, late-stage treatments.

About CYduct Diagnostics, Inc.

CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare markets across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for screening, diagnosis, treatment and management of disease and medical conditions.

Additional information on its line of products will be available on the Company's website at: [www.CYductDX.com](http://www.CYductDX.com)

#### FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION

This press release includes certain information that may constitute forward-looking statements. Forward-looking statements are typically identified by terminology such as "could," "may," "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "proposed," "planned," "potential" and similar expressions, or are those, which, by their nature, refer to future events. All statements, other than statements of historical fact, included herein, including statements about CYduct's beliefs and expectations, are forward-looking statements. Forward-looking information is necessarily based upon a number of assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Although CYduct believes that such statements are reasonable, it can give no assurance that such forward-looking information will prove to be accurate. CYduct cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors. Accordingly, due to the risks, uncertainties and assumptions inherent in forward-looking information, readers and prospective investors in the Company's securities should not place undue reliance on forward-looking information. All forward-looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof and is subject to change. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at [www.otcmarkets.com](http://www.otcmarkets.com)). The Company assumes no obligation to revise or update forward-looking information to reflect new circumstances, whether as a result of new information, future events or otherwise, except as required by law.

#### CONTACT:

CYduct Diagnostics, Inc.

Investor Relations +1-888-545-9112

SOURCE: CYduct Diagnostics, Inc.

Elise Grubb  
CYduct Diagnostics  
+1 800-388-6445

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/822721139>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.